

Recent Development of Aminoacyl tRNA Synthetase Inhibitors for Human Diseases: A Future Perspective.

Soong-Hyun Kim, Seri Bae, Minsoo Song*

New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), 80 Cheombok-ro Dong-gu Daegu 41061, Korea

Abstract

Aminoacyl-tRNA synthetases (ARSs) are essential enzymes for translating amino acids for protein synthesis. Their function in pathogen-derived infectious diseases has been well established, which has led to development of small molecule therapeutics. The applicability of ARS inhibitors for other human diseases such as fibrosis has recently been explored in the clinical setting. There are active studies to find small molecule therapeutics for cancers. Studies on central nervous system (CNS) disorders are burgeoning as well. In this regard, we present a concise analysis of the recent development of ARS inhibitors based on small molecules from the discovery research stage to clinical studies as well as a recent patent analysis from the medicinal chemistry point of view.

Keywords: aminoacyl-tRNA synthetase, small molecule inhibitors, human diseases

1. Introduction

Aminoacyl-tRNA synthetases (ARSs) are a family of 20 essential enzymes that ligate amino acids to their corresponding tRNAs and translate the genetic code during protein synthesis [1]. The two-step catalytic reaction of ARSs involves the formation of an enzyme-bound aminoacyl-adenylate (AMP-aa) followed by the formation of aminoacylated-tRNA (tRNA-aa) by transferring the amino acid to the corresponding tRNA. This catalytic reaction of ARSs plays a pivotal role in protein synthesis, which is essential for the growth and survival of all

cells (Figure 1). ARSs have long been studied as therapeutic targets for pathogen-derived infectious diseases predominantly because of concerns that ARS catalytic site inhibitors would block translation in normal cells [2-4]. In this regard, various seminal reviews have discussed ARS inhibitors for the development of antibiotics from different perspectives [5-9].




Figure 1. Two-step catalytic reaction of aminoacyl-tRNA synthetases (ARSs). ARSs use an amino acid (aa), ATP, and tRNA as substrates to produce tRNA-aa that leads to protein synthesis in the ribosome.

However, a significant amount of research targeting mammalian ARS for the treatment of human diseases have recently emerged. For example, febrifugine derivatives, including halofuginone which targets prolyl-tRNA synthetase (ProRS), are under investigation for the treatment of cancer, fibrosis, and inflammatory diseases [10-11]. Additionally, threonyl-tRNA synthetase (ThrRS) was identified as a target protein of antiangiogenic borrelidin [12], and a peptide fragment derived from tryptophanyl-tRNA synthetase (TrpRS) is of interest as a possible antiangiogenic agent [13]. Accordingly, Kwon *et al.* [14] separately provided thorough reviews on the physiology, pathology, and structural aspects of ARSs, as well as the development of ARS inhibitors for human diseases including infectious diseases, cancer, inflammatory diseases and CNS disorders. From this review, we focus on the recent development of ARS inhibitors ranging from discovery to clinical trials from medicinal chemistry perspectives and provide a related patent analysis.

2. Structural class of ARS inhibitors

2.1. Benzoxaboroles

Benzoxaboroles are a class of boron-containing compounds with a broad range of biological activities. A subset of benzoxaboroles have antimicrobial activity primarily due to their ability to inhibit leucyl-tRNA synthetase (LeuRS) via the oxaborole tRNA-trapping mechanism, which involves the formation of a stable tRNA^{Leu}–benzoxaborole adduct in which the boron atom interacts with the 2'- and 3'-oxygen atoms of the terminal 3' tRNA adenosine [15]. Benzoxaboroles' antimicrobial activity is due to their inhibition of leucyl-tRNA synthetase (LeuRS) via the oxaborole tRNA-trapping (OBORT) mechanism. In a related study, researchers at Anacor Pharmaceuticals reported an X-ray crystal structure of *Thermus thermophilus* LeuRS complexed with tRNA^{Leu} and the LeuRS inhibitor benzoxaborole **AN2690** to form a tRNA-**AN2690** adduct possessing tetrahedral spiroborate structure **1** (Figure 2) [16]. The tetrahedral spiroborate adduct was stabilized by the formation of covalent bonds between the Lewis acidic boron atom and the 2'- and 3'-oxygen atoms of the tRNA's 3'-terminal adenosine as a nucleophile [17-18]. The oxaborole scaffold can reversibly form covalent tetrahedral complexes with nucleophiles such as hydroxyl groups because of the presence of the heterocyclic boron atom, which has an empty p orbital. Targets for these compounds include β -lactamases, PDE4 nucleotide phosphodiesterase, ROCK kinase, carbonic anhydrase, and LeuRS [19].




Figure 2. AN2690-tRNA^{Leu} adduct via the OBORT mechanism.

A recent example of the benzoxaborole class of inhibitors is the nitrophenyl sulfonamide-based benzoxaborole **PT638**; Si *et al.* investigated **PT638** to determine its mode of action [15]. The finding that **PT638** has potent antibacterial activity against methicillin-resistant *Staphylococcus aureus* (*S. aureus*, MRSA) (MIC of 0.4 µg/mL) and does not inhibit *S. aureus* LeuRS (*Sa* LeuRS) (IC₅₀ > 100 µM) suggests the possibility that it has targets other than LeuRS. Selection for resistance to **PT638** using MRSA and whole-genome sequencing of three colonies that showed MICs of ≥ 3.125 µg/mL resulted in three mutations in the LeuRS gene including D343Y, G302S, and F233I, all of which are located within the editing domain of *Sa* LeuRS, thereby confirming *Sa* LeuRS as the target of **PT638**. A metabolism study of **PT638** using MRSA cell lysate and a SAR study of **PT638** analogs revealed that **PT638** might be a prodrug that can be reduced to its amine analog **PT662** mainly by nitroreductase NfsB in MRSA (Figure 3).





Figure 3. Benzoxaborole **PT638** is reduced by nitroreductase to **PT662**.

In a related study, GSK developed a series of 3-aminomethylbenzoxaborole derivatives **4** and **5** that target *Mtb* LeuRS [20]. The boron atom in the molecules was critical for *Mtb* LeuRS activity since it forms a bidentate covalent adduct with the terminal nucleotide of tRNA, Ade76, and traps the 3' end of tRNA^{Leu} in the editing site to inhibit leucylation and thus protein synthesis. The (*S*)-aminomethyl side chain at C-3 **4** and **5** was critical for binding, and 4-halogen atoms (Cl and Br) significantly improved *Mtb* LeuRS activity, antitubercular activity

against *Mtb* H37Rv, and selectivity against other bacteria. However, potential toxicity issues from the inhibition of mammalian cytoplasmic LeuRS and tolerance issues of **5** in a once daily dose of 50 mg/kg in a mouse acute TB infection model caused serious concerns for its use as a TB drug in long-term therapy. Throughout a series of medicinal chemistry campaigns to examine the structure-activity relationship (SAR) of 3-aminomethylbenzoxaborole derivatives, **6–10** were found to improve both selectivity against human cytoplasmic LeuRS and HepG2 cell toxicity compared to **4** and **5**, presumably by decreased lipophilicity and increased polarity in the molecule (Figure 4) [21]. Triaging lead compounds through in vivo PK analysis and efficacy assays using acute and chronic mouse TB infection models identified **8** (**GSK656**) as a preclinical candidate for tuberculosis; **8** successfully completed its first-time-in-human (FTIH) study to evaluate the safety, tolerability, pharmacokinetics, and food effects of single (5, 15, and 25 mg) and repeat oral doses (5 and 15 mg, 14 days, qd; NCT03075410) [22]. Moreover, **8** is currently in a phase 2 clinical trial for drug-sensitive pulmonary tuberculosis to evaluate its early bacterial activity, safety, and tolerability (NCT03557281). Details of the clinical studies of **8** will be discussed in a later section.



Cladosporin isolated from *Cladosporium cladosporioides* and *Aspergillus flavus* was found to have potent antimalarial activity against both liver and blood stage *Plasmodium falciparum* by targeting the parasite cytosolic lysyl-tRNA synthetase (*Pf* LysRS) and terminating protein biosynthesis [23]. Despite its high clearance and poor oral bioavailability in vivo [24-25], the favorable selectivity and potency shown by cladosporin against *Pf* LysRS over human LysRS spurred medicinal chemistry efforts to further develop it to overcome its metabolic limitations as an oral drug. In this regard, Rusch *et al.* analyzed cladosporin by incubating it with mouse liver microsomes in vitro and revealed that three major metabolically weak points might cause the metabolic liabilities of cladosporin (Figure 5) [26]. The hydroxyl group, tetrahydropyran, and C-4 of isochromenone were potentially the three major metabolically weak points. Additionally, the X-ray crystal structure of cladosporin and *Plasmodium falciparum* LysRS (*Pf* LysRS) suggested an H-bond with Glu332 and the π /cation 'cage' from adjacent aromatic and charged residues and the interaction between the lactone ring and Arg559 through water as the major interactions [27]. Based on these basic findings, medicinal chemistry efforts were focused on the three metabolically weak points of cladosporin to generate three major derivatives, A, B, and C, as a representative example. Upon screening these libraries, the unsaturation of the isocoumarin core and transformation of the metabolically unstable tetrahydropyran ring to the cyclohexyl ring yielded a selective LysRS inhibitor with improved metabolic stability at the level of hepatic extraction. In line with a previous report by Rusch *et al.* focusing on metabolic weak points of cladosporin, Zhou *et al.* confirmed that the methyl tetrahydropyran moiety of cladosporin could be replaced by a more stable methylcyclohexane while maintaining potency in the ATP hydrolysis assay (compounds **15**, **16**) [28]. The methyl group in the cyclohexane ring was important for the hydrophobic interaction with Ser344, resulting in increased potency 4-fold compared to that of compound **15**. The replacement with

a lactam group or a conjugated $\Delta^{3,4}$ double bond within the isocoumarin ring was tolerated, but the two phenolic hydroxyl groups were critical for binding to LysRS (Figure 5).




Figure 5. Optimization of **cladosporin** to improve pharmacokinetic properties.

Another medicinal chemistry campaign to develop a new antimalaria and anti-cryptosporidiosis drug targeting *Pf* LysRS1 and *Cp* LysRS was continued by Baragaña *et al.* using cladosporin as a starting point [29]. Its low druggability due to high metabolic instability was optimized by replacing the isocoumarin core with the chromone scaffold connected to a metabolically stabilized cyclohexane ring with an amide linker, as shown in Figure 6. Compound **21** was active against both *Pf* LysRS1 ($IC_{50} = 0.015 \mu$ M) and whole-cell bloodstream *P. falciparum* 3D7 ($EC_{50} = 0.27 \mu$ M) and was selective compared with *Hs* LysRS

(IC₅₀ = 1.8 μ M). The pharmacokinetic properties were optimized by stabilizing the metabolically labile cyclohexyl ring and blocking the point of potential hydroxylation of the phenyl group in the chromone core. As a result, compound **21** showed good systemic exposure with excellent oral bioavailability (F = 100%) and a moderate half-life (T_{1/2} = 2.5 h). In vivo efficacy was evaluated using a NODscidIL2R γ null mouse (SCID) model up to 40 mg/kg (p.o.), and it was found that a daily oral dose of ED₉₀ = 1.5 mg/kg (1.0–2.3 mg/kg) (estimated daily exposure in blood AUC_{ED90} = 11,000 ng·h/ml/d [6,900–14,000 ng·h/ml/d]) reduced parasitemia by 90%. A high level of sequence identity within the active-site region of *Pf* LysRS1 and *Cp* LysRS (96% identity) and an overall sequence identity of 47.7% and similarity of 64.6% across the entire protein derived the evaluation of compound **21** against *Cryptosporidium parvum* (*C. parvum*) both in vitro and in vivo. Compounds for cryptosporidiosis treatment must also have good exposure in the gastrointestinal tract and possibly also some systemic exposure since the parasite is found predominantly in the gastrointestinal tract with some in the biliary tract. In this regard, compound **21** was worthy of consideration for cryptosporidiosis since 17% of the oral dose was found in mouse stools, suggesting that some biliary excretion had occurred. Compound **21** showed efficacy in vivo in two different *Cryptosporidium* mouse models, NOD SCID gamma and INF- γ -knockout, at 20 mg/kg (p.o.). However, the toxicity concern of **21** at 50 mg/kg in mice (p.o.) at which the blood concentration in mice reached the EC₅₀ for HepG2 cells limited further development. It is presumed that the toxicity is due to the inhibition of mammalian LysRS.




Figure 6. Optimization of **cladosporin** by replacing the core with chromone scaffold.

2.3. Borrelidin

Borrelidin is known as a potent inhibitor of threonyl-tRNA synthetase (ThrRS) for malaria. However, its lack of selectivity against human ThrRS and high toxicity to human cells limit further development as a drug candidate. In this regard, Novoa *et al.* derived a series of borrelidin analogs that circumvent these potential problems by showing higher selectivity and lower cytotoxicity from minor structural changes in the carboxylic acid side chain [30]. In particular, compounds **BC196 (23)**, which released rotational constraints by adopting linear carboxylic acid, and **BC220 (24)**, which converted terminal carboxylic acid to pyridyl ethyl ester on the cyclopentane ring, showed improved selectivity against *P. falciparum* over human HEK293 cells by 13,579- and 4,048-fold, respectively. Considering that borrelidin exhibited 355-fold activity difference between *P. falciparum* and human HEK293 cells, selectivity was improved by 11~38 fold. From in vivo efficacy studies using a *P. yoelii* 17XL-infected mouse model, **23** and **24** showed 100% survival over 20 days after drug treatment at 6 mg/kg per day. In particular, **24** showed complete clearance of parasites in the blood at 6 mg/kg per day, 80% survival and ~3% parasitemia at 0.25 mg/kg per day. It is also interesting that **24** was not cleaved to borrelidin by esterase, as determined in time course experiments with infected red

blood cells (RBCs) over 27 h, suggesting that the biological effect of **24** is not due to its conversion to borrelidin by RBCs or plasmodial esterases (Figure 7).




Figure 7. Optimization of borrelidin selectivity for *P. falciparum* over human ThrRS.

2.4. Benzothiazoles

Unlike other LysRS inhibitors that target the active site of pathogen-derived LysRS, Kim *et al.* reported a new class of small molecule inhibitors, **YH16899**, that bind to human LysRS without affecting the catalytic activity of LysRS [31]. Physiologically, it is known that LysRS binds to 67-kDa laminin receptor (67LR), a target for antimetastatic therapeutics [32], in the plasma membrane and enhances cell migration that causes cancer metastasis. Thus, it is thought that directly inhibiting the interaction between LysRS and 67LR by a small molecule could suppress cancer metastasis and derive a new class of antimetastatic cancer therapy. In this regard, **25** showed specific inhibition of the binding between the LysRS and 67LR pair based on in vitro pull-down and immunoprecipitation (IP) assays and decreased the amount of membranous 67LR using LysRS-overexpressing H226 squamous lung carcinoma cells (Figure 8). The in vivo efficacy of **25** was demonstrated using three different in vivo mouse models, including (i) a mouse breast cancer model (4T1 cells, 100 mpk and 300 mpk, p.o., ~60% inhibition of tumor metastasis), (ii) a Tg(MMTV-PyVT) model (100 mpk, p.o., ~70% reduction of pulmonary

nodule formation), and (iii) a cancer cell colonization model (A549 cells expressing RFP, ~50% reduction of tumor metastasis in the brain and bone tumors over 7 weeks). Overall, Kim *et al.* showed that the protein-protein interaction of LysRA-67LR is a promising approach for the development of new therapeutics for human diseases.




Figure 8. YH16899, a protein-protein interaction inhibitor of LysRA-67LR.

2.5. Halofuginone

Halofuginone (**HF**, **26**), a well-known antifibrotic agent in preclinical and clinical studies, inhibits prolyl-tRNA synthetase (ProRS) activity [10]. Mechanistically, **26** competitively binds to the proline binding pocket of the catalytic site of ProRS and causes drug resistance due to the accumulation of proline [33]. Because a higher concentration of proline is often observed in fibrotic tissue than in nonfibrotic tissue [34], it is anticipated that the antifibrotic effect of **26** would be diminished in fibrotic tissue. In this regard, Shibata *et al.* from Takeda Pharmaceuticals developed **T-3833261 (27)**, a potent ATP competitive inhibitor of ProRS that does not bind to the proline binding site [11]. The antifibrotic activity of **27** was evaluated both in vitro and in vivo. From the TGF-β-induced fibrotic assay, **27** inhibited the expression of fibrotic markers, including α-smooth muscle actin (α-SMA) and type I collagen (Colla), by reducing Smad3 expression in human skin fibroblasts. These results were directly correlated with the in vivo TGF-β-induced mouse model. The topical application of **27** reduced the expression of fibrotic genes such as Colla1, Colla2, and α-SMA (Figure 9).




Figure 9. Antifibrotic ProRS inhibitors halofuginone and T-3833261.

In a related study, it is presumed that the proline-rich nature of profibrotic proteins such as collagens may be attributed to glutamyl-prolyl-tRNA synthetase (GluProRS)-mediated translational regulation during cardiac fibrosis. Several studies with indirect evidence support the regulatory role of GluProRS as a target gene for cardiac fibrosis. For example, hypoactive mutations in the ProRS domain of GluProRS lead to hypomyelinating leukodystrophy without causing any known cardiac dysfunction in patients, implying that reduced ProRS enzymatic activity may not adversely affect normal heart function while reducing proline-rich protein synthesis [35]. In this regard, Akashi Therapeutics used **26** to treat Duchenne muscular dystrophy (DMD), analogous to reducing fibrosis by **26** and increasing muscle strength [36-39]. Recently, Wu *et al.* examined GluProRS-mediated regulatory mechanisms of profibrotic protein synthesis at the translational level and identified increased GluProRS in failing human and mouse hearts [40]. Increased GluProRS contributed to the elevated translation of proline (Pro)-rich (PRR) mRNAs, and genetic knockout of *Eprs* reduced fibrosis in different heart failure mouse models. Additionally, the selective GluProRS inhibitor **26** reduced the translation of PRR mRNAs, such as collagens and other novel PRR genes including LTBP2 and SULF1.

2.6. Sulfonamido propanamides and 2-aminopyrimidines

Aminoacyl-tRNA synthetase-interacting multifunctional protein 2 (AIMP2), a scaffold in the multi-tRNA synthetase complex (MSC), dissociates from the MSC and influences the activity

of the p53, TGF- β , TNF- α and WNT signaling pathways [41-42]. A splicing variant of AIMP2 lacking exon 2 (AIMP2-DX2) correlates positively with cancer by compromising the tumor-suppressive function of native AIMP2 through competitive interactions with p53 FBP and TRAF2 [43]. Lim *et al.* showed that AIMP2-DX2 binds with HSP70 and is stabilized by blocking the Siah1-dependent ubiquitination of AIMP2-DX2, which leads to cancer progression in vivo [44]. Based on this mode of action of AIMP2-DX2, the protein-protein interaction inhibitor **BC-DXI-495 (28)** was found to specifically inhibit the AIMP2-DX2 + HSP70 interaction and suppress cancer cell growth in vitro (IC_{50} 4.2 μ M, luciferase assay; EC_{50} 14.2 μ M, cell viability assay, A549 cells) and AIMP2-DX2-induced tumor growth in vivo (~50% decrease, 50 mpk, i.p., 2 weeks, H460 stably expressing AIMP2-DX2 WT, BALB/Cslc mice). Consecutively, Sivaraman *et al.* reported **BC-DXI-843 (29)**, which was optimized from **BC-DXI-495** [45]; **29** significantly improved in vitro activity in luciferase and cell viability assays (IC_{50} 0.92 μ M, luciferase assay; EC_{50} 1.2 μ M, cell viability assay, A549 cells). The in vivo efficacy of **29** in the H460 xenograft mouse model was comparable with that of **28** by inhibiting ~60% tumor growth (50 mpk, bid, i.p., 2 weeks). In the same context, Lee *et al.* separately developed 2-aminophenylpyrimidine derivative **30** for AIMP2-DX2 interaction inhibition with > 80% tumor growth inhibition in an H460 xenograft mouse model [46].




Figure 10. AIMP2-DX2 interaction inhibitors.

3. Aminoacyl-tRNA synthetase (ARS) therapeutics in patents

As mentioned before, much research on eukaryotic aminoacyl-tRNA synthetase (*eARS*) has recently been conducted to determine the different roles of human ARS other than being the “housekeeping” enzyme for protein synthesis in various human diseases [14]. Human ARS has also become a major target in treatment of proliferative diseases such as cancers, inflammatory diseases, autoimmune diseases and fibrosis. In this section, we discuss patents related to therapeutic development targeting both prokaryotic and eukaryotic ARSs. Since Gadakh *et al.* at the Rega Institute for Medical Research reported a patent review on ARS inhibitors as antimicrobial agents in 2012 [7], we specifically analyzed patents from 2013 to present day. From the SciFinder® search, eight relevant patents were identified, and we present them in alphabetical order of ARS targets.

3.1. Glycyl-tRNA synthetase (GlyRS) inhibitors

Professors Schimmel and Yang at the Scripps Research Institute disclosed 4-glycylsulfamoyladenine derivatives (**GlySAs**, Figure 11) as human glycyl-tRNA synthetase (GlyRS) inhibitors for cancer therapy by lowering neddylation [47]. The covalent attachment of neural precursor cell expressed developmentally downregulated gene 8 (NEDD8) to the core cullin protein of cullin-RING ligase E3s (CRLs, e.g., Ubc12), so-called neddylation, is a crucial process for the ubiquitination of multiple protein substrates mediated by GlyRS. GlyRS is highly expressed in most malignant cancers, such as breast cancer, ovarian cancer, and lung cancer. Selective binding of **GlySAs** to the catalytic domain of human GlyRS inhibited the attachment of NEDD8, consequently reducing the level of neddylation by more than 50% in various cancer cells. Interestingly, **GlySAs** do not significantly influence the function of GlyRS in aminoacylation. The patent provided the systematic MOA evaluation of GlyRS in the neddylation pathway and the confirmation of GlyRS inhibition with the crystal structure of **GlySA (31)** binding to human GlyRS (pdb code: 2ZT8). **GlySAs** were screened with the NCI 60 cell panel assay at a single dose of 5~10 M, and **GlySA (31)** possessed a potency of 0.372

to 3.715 μM GI_{50} values in 58 cancer cell lines. With the lung metastasis model induced by MDA-MB-231 cells, **31** was administered via intravenous injection twice a week at a dose of 4 mg/kg ($n = 10$). After 10 days of injection of GlyRS inhibitors, **31** reduced lung metastasis in the mouse model with 69% efficacy, which is greater than that of **MLN4924** (4.4 mg/kg, 40% efficacy), and has been tested in clinical trials.




Figure 11. The structure of **GlySAs** as eukaryotic GlyRS inhibitors

3.2. Leucyl-tRNA synthetase (LeuRS) inhibitors

Oxford Drug Design Ltd. has reported a leucyl-tRNA synthetase (LeuRS) inhibitor of 2-amino-*N*-(arylsulfinyl) acetamide compounds as an antibiotic agent [48]. They prepared a series of 46 compounds and their corresponding TFA salts, as shown in Figure 12, of which the dissociation constants (K_d) were measured for *E. coli* LeuRS by isothermal titration calorimetry (ITC) and were found to range from 1.39 nM to 9130 nM. The antibacterial activity of the 26 compounds was evaluated in 7 bacterial strains (ATCC25922, EFFLUX, B1966, ATCC700603, ATCC27853, B1931, and ATCC49247) with MIC values of 0.25 ~ >64 mg/L, and compound **35** was the most potent compound with MIC values in all strains (0.5, 0.25, 1, 1, 32, 2, and 4 mg/L, respectively) comparable to those of the controls, such as ciprofloxacin, ceftazidime, meropenem, and azithromycin. No compound showed any potential cytotoxic effects against the human hepatic cell line HepG2 (ATCC HB-8065).






Figure 12. Synthesis of 2-amino-*N*-(arylsulfinyl) acetamide compounds and the structure of the prokaryotic LeuRS inhibitor **35**.

Jirgensons *et al.* at the Latvian Institute of Organic Synthesis developed *N*-aminoacyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase (ARS) inhibitors for the treatment of bacterial infections [49]. Arylsulfonyl chlorides were converted to the corresponding arylsulfonamides, in which the terminal amine was coupled with amino acids to provide 52 compounds of *N*-aminoacyl-arylsulfonamides, as shown in Scheme 1. All compounds were tested for *in vitro* enzyme inhibition assays against leucyl-, valyl- and isoleucyl-tRNA synthetases (LeuRS, ValRS, and IleRS, respectively) from *Escherichia coli* (*E. coli*) and *Staphylococcus aureus* (*S. aureus*) and showed IC₅₀ values of 0.0034 ~ >50 μM for *E. coli* LeuRS and 0.26 ~ >50 μM for *S. aureus* LeuRS. However, none of the compounds presented any proper antibacterial activities at concentrations of 50 μM or below against IleRS and ValRS from *E. coli* and *S. aureus*. Therefore, the scope of substituents on the phenyl ring was investigated further. It was found that the valine of the amino acid and meta-substituted phenyl ring of the aryl group significantly increased the inhibition of LeuRS from *E. coli* and *S. aureus* with submicromolar activity (Figure 13) (*e.g.*, IC₅₀ values of compound **42**: 0.002 μM for *E. coli* and 0.33 μM for *S. aureus*).



Scheme 1. Synthesis of *N*-aminoacyl-arylsulfonamides.



7 compounds with <1 μM activity for *LeuRS* inhibition from *E. coli* and *S. aur*

R_1	IC_{50} of <i>LeuRS</i> (μM)	
	<i>E. coli</i>	<i>S. aureus</i>
chloro- (36)	0.031	0.92
phenyl- (37)	0.032	0.65
2-amino-6-(methylamino)pyrimidin-4-yl- (38)	0.051	0.26
pyridin-4-yl- (39)	0.013	0.81
2-aminopyridin-4-yl- (40)	0.002	0.33
2,6-diaminopyrimidin-4-yl- (41)	0.02	0.72
4-amino-1,3,5-triazin-2-yl- (42)	0.0034	0.53



Figure 13. Representative examples of *N*-aminoacyl-arylsulfonamides and their inhibitory activities against *LeuRS* from *E. coli* and *S. aureus*.

3.3. Methionyl-tRNA synthetase (MetRS) inhibitors

The Buckner group at the University of Washington found that compounds bearing *N*-containing heteroaromatic bicyclic rings inhibit methionyl-tRNA synthetase (MetRS) for antibacterial treatment [50]. A total of 249 compounds with 4 major different scaffolds were synthesized and tested in 13 different *in vitro* assays against MetRS (*Trypanosoma brucei*) ATP depletion (A), MetRS (*Staphylococcus aureus*) ATP depletion (B), MetRS (*Brudella*) ATP depletion (C), MetRS (*Giardia*) aminoacylation (D) *Trypanosoma brucei* (E), *Trypanosoma cruzi* (F), *Giardia intestinalis* (ATCC50508) (G), *L. amaz* (H), *Plasmodium falciparum* (3D7) (I), *Staphylococcus aureus* (ATCC29213) (J), *Staphylococcus aureus* MRSA (ATCC43300) (K), *Enterococcus faecalis* (ATCC29212) (L), and *Enterococcus faecium* (ATCC51559) (M). Two compounds bearing the same scaffold of pyridoimidazole, **43** and **44**,

showed excellent potency in bacterial MetRS inhibition (IC_{50}), bacterial growth inhibition (EC_{50}), and MIC values in most of the *in vitro* cell assays (Figure 14).

four major scaffolds of MetRS inhibitors



	A	B	C	D	E	F	G	H	I	J	K	L	M
	IC_{50} (nM)				EC_{50} (nM)					MIC (mg/L)			
X=O (43)	8	19	-	2	1.70 0.18 0.05	4.57 5.05	664.0 492.0	1301.2 1134.2	-	-	-	-	>0.04
X=N (44)	28	28	-	3	0.91 0.67 0.06 0.41	4.57 3.72	590.0 316.0	2852.4	-	0.157	0.157	>0.04 0.079	>0.04

Figure 14. Four major scaffolds of bacterial MetRS inhibitors and the biological activities of **43** and **44** against 13 different bacterial cell lines.

The Martin group at the University of Texas at Austin reported *Trypanosoma brucei* (*T. brucei*) methionyl-tRNA synthetase (MetRS) inhibitors for the treatment of African trypanosomiasis and sleeping sickness [51]. Two major classes of compounds incorporating tetracyclic tetrahydro-beta-carboline and 4-amino-2-piperidone were prepared to selectively inhibit the MetRS of *T. brucei*. The inhibitory activities of three tetracyclic carboline compounds were tested for the *T. brucei* MetRS aminoacylation assay, showing submicromolar IC_{50} values as depicted in Figure 15. One of the tetracyclic compounds exhibits no off-target activity when screened against a panel of 45 CNS proteins.






Figure 15. Structures of 3 tetracyclic carboline compounds (**45–47**) and their inhibitory activities against the aminoacylation of *T. brucei* MetRS.

Additionally, the internal C-C bond of piperidine was removed to yield 37 4-amino-2-piperidones, including **48–59**, which were screened for *T. brucei* growth inhibition at a single dose (1 μM or 10 μM). Eleven compounds (**48–58**) showed decreased activity in the *T. brucei* growth inhibition assay by showing more than 80% inhibition at 10 μM; **59** with a methoxy on the C-5 of the indole ring showed better activity with ~ 60% inhibition at 1 μM (Table 1).



59
Inhibition : ~ 60 @ 1 μM
 ~ 98 @ 10 μM













ID	R ₁	R ₂	n	% inhib. (10 μM)	ID	R ₁	R ₂	n	% inhib. (10 μM)
48			1	97	54			1	93
49				93	55				85
50				98	56			1	95
51				92	57			0	99
52				98	58			2	96
53				94					

Table 1. *T. brucei* growth inhibition by 4-amino-2-piperidone compounds (**48~58** and **59**).

3.4. Phenylalanyl-tRNA synthetase (PheRS) inhibitors

The Kahne group at Harvard University developed tRNA synthetase inhibitors of secondary amines for killing gram-negative bacteria and treating tuberculosis [52]. Although the target enzyme is not specifically mentioned in their patent, phenylalanyl-tRNA synthetase (PheRS; FARS) might have been explored due to the specific note about FARS in the table of antimicrobial activity. They synthesized 458 secondary amines, one tertiary cyclic amine, 15 tertiary cyclic amides and one tertiary cyclic carbamate compound. The antimicrobial activities of each compound were measured via the gram-negative (*E. coli* and *Acinetobacter baumannii* [*A. bau*]) MIC protocol and tuberculosis luminescence assay. Among these compounds, the methyl substitution of R₆ and ortho substitution of R₅ on the secondary benzylic amine significantly increased the antimicrobial activities (Figure 16). In particular, the para- or meta-methyl substitution of R₈ provided the most potent antimicrobial compounds, **63** and **64** with MIC values of 33 μ M (*E. coli* WT), less than 1 μ M (*E. coli* Δ -TolC), and 33 μ M (*A. bau*) against gram-negative bacteria as well as *Mycobacterium tuberculosis* (MTB) activity of 10 μ M against H37Rv WT. Furthermore, they showed that combination treatment of compound **65** (R₁-R₆ = -H, R₇ = -1-cyclohexene, HCl salt) and AN3365 (a LeuRS inhibitor) dramatically decreased the viability of bacterial cells, suggesting that the combination therapy could attenuate antibiotic resistance, thus expanding the lifespan of antibiotics.




Figure 16. Structures of the secondary benzylamines with antimicrobial activities via

prokaryotic PheRS inhibition.

3.5. Prolyl-tRNA synthetase (ProRS) inhibitors

Daewoong Pharmaceutical Co. has unveiled heterocyclic compounds to inhibit abnormal human prolyl-tRNA synthetase (ProRS) activity for the treatment of cancers, inflammatory diseases, autoimmune diseases, and fibrosis [53]. A total of 230 nitrogen-containing heteroaromatic compounds with various substitutions were synthesized and categorized into three groups in terms of their biological activities to inhibit the human ProRS enzyme, as shown in Figure 17. The IC_{50} values of 26 compounds (**class A**) are 100 nM or less, the values of 89 compounds (**class B**) range from 100 to 500 nM, and the values of 115 compounds (**class C**) are 500 nM or higher. Compounds in **class A** share disubstituted imidazolyl aromatic bicyclic rings yielding potent human ProRS inhibition.

<i>h</i> -ProRS enzyme IC_{50} (nM)	# of compounds
class A < 100	26
100 < class B < 500	89
class C > 500	115

Class A: disubstituted imidazole bicycle
26 compounds




Figure 17. Human ProRS inhibitors for antiproliferative diseases and the most potent imidazolyl aromatic bicycle compounds (class A).

3.6. Multi-tRNA synthetase inhibitors

The Qi group at the University of Florida prepared 23 sulfamide adenosine derivatives as aminoacyl-tRNA synthetase inhibitors for the treatment of proliferative diseases such as cancers, inflammatory diseases, and autoimmune diseases [54]. As described in Figure 18, a protected adenosyl amine was extended as the protected adenosyl sulfamide, of which the terminal amine was coupled with the different kinds of amino acids to complete the synthesis of the aminoacyl sulfamide adenosine compounds (**aa-SA**). The cell viability assay of the **aa-SAs** was performed in prostate cancer cell lines, and IC_{50} values of 0.0015 ~ 27 μ M for

LNCaP and 0.0011 ~ 16 μ M for PC3 were observed.




Figure 18. Synthetic scheme of sulfamide adenosine derivatives (**aa-SA**) and their biological activities against prostate cancer cell lines.

For **L-Gln-lactam-SA (87)**, a panel of other cancer cell lines was tested for cell viability; cytotoxic activities (IC₅₀) of 0.19 ~ 25.24 μ M were observed (Table 2). Additionally, apoptotic staining and cell cycle/arrest assays were performed on LNCaP and PC3 cells for all **aa-SA** compounds. **aa-SA**-induced apoptosis and a shift of the cell cycle to the sub G0/G1 and S phases were observed (Table 2).

a panel of cancer cell lines	IC ₅₀ (μ M) of L-Gln-lactam-SA (87)
MOLT-4 (human acute lymphoblastic leukemia)	2.44
HL60 (human acute promyelocytic leukemia)	0.46
MDA231 (breast cancer)	11.03
A549 (lung cancer)	7.93
HCT116 (colon cancer)	1.48
HeLa (cervical cancer)	25.24
MCF-7 (breast cancer)	0.19

Table 2. Cytotoxicity of **L-Gln-lactam-SA (87)** against a panel of cancer cell lines

4. Aminoacyl-tRNA synthetase (ARS) therapeutics in clinical trials

Since FDA approval of the natural product **mupirocin** (IleRS inhibitor) to treat bacterial infections, prokaryotic ARS has attracted much attention as one of the most promising targets for developing antimicrobial therapeutics in recent years. Nevertheless, **AN2690** (a synthetic small molecule, Tavaborole®) is the only FDA-approved drug for nail onychomycosis to inhibit fungal LeuRS. In this section, we discuss small molecule therapeutics that are undergoing clinical trials as prokaryotic or eukaryotic aminoacyl-tRNA synthetase (ARS) inhibitors. A recent review published in *Nature Reviews Drug Discovery* (2019) by the Kim group at the Medical Bioconvergence Research Center described the ARS inhibitors that are currently being evaluated in clinical trials [14]. Thus, this review will provide the latest updates on the clinically active compounds based upon their reported clinical outcome. The Cortellis search (2020-10-08) with the keywords “tRNA synthetase inhibitor” and status of “phase 1 clinical”, “phase 2 clinical”, “phase 3 clinical”, and “clinical” revealed that five small molecule therapeutics, including **DWN12088**, **CRS3123**, **GSK3036656**, **mupirocin** bioadhesive gel, and **DWP17011**, are being actively evaluated in clinical studies (Table 3). Since **mupirocin** has already been marketed for bacterial skin infection and information on **DWP17011** is fairly limited, clinical trials of the remaining three compounds will be discussed in this section.

Drug Name	Company	Target	Indications	Status	Clinical Trial # (country)
DWN12088	Daewoong Pharma.	eProRS	IPF; Scleroderma	Ph I	ACTRN12619001239156 (AU)
CRS3123	Crestone	pMetRS	CDI; HPI	Ph I	NCT01551004 (US) NCT02106338 (US)
GSK3036656	GSK	pLeuRS	MTBI	Ph I	NCT03075410 (UK) NCT03557281 (SA)
Mupirocin bioadhesive gel	Laboratorios Ojer Pharma	pIleRS	BSI; Impetigo	Ph III	Not specified (SP)
DWP17011	Daewoong Pharma.	eProRS	Fibrosis	Ph I	Not specified (KR)

Table 3. A list of small molecules in clinical trials for the development of ARS inhibitors (IPF: idiopathic pulmonary fibrosis, CDI: *Clostridium difficile* infection, HPI: *Helicobacter pylori* infection, MTBI: *Mycobacterium tuberculosis* infection, BSI: bacterial skin infection).




Figure 19. Chemical structures of **DWN12088** and **CRS3123**.

4.1. **DWN12088**, eukaryotic prolyl-tRNA synthetase (eProRS) inhibitor

Excessive deposition of collagen is pathologically considered the main cause of fibrosis, and proline residues are the major constituents of collagen. Therefore, an eProRS inhibitor would downregulate collagen synthesis and would be a potential therapeutic agent against fibrosis. Daewoong Pharmaceutical Co., Ltd. developed **DWN12088 (89)** (Figure 19), one of the **class A** compounds (eProRS IC_{50} = 78 nM) covered in the aforementioned patent (WO 2018147626 A1), for the treatment of idiopathic pulmonary fibrosis (IPF). In IPF patient-derived primary lung fibroblasts, treatment with **89** reduced the synthesis of collagen and α -smooth muscle actin (α -SMA) under transforming growth factor- β (TGF- β) induction. In the mouse model of bleomycin-induced pulmonary fibrosis, oral administration of **89** for 2 weeks significantly reduced cardiac fibrosis (ED_{50} = 0.4 mg/kg, *in vitro*) and the collagen amount in lung tissues and bronchoalveolar lavage fluid (BALF) [55]. Remarkably, **89** provided considerable repair of lung function in this mouse model, as measured by whole-body plethysmograph. GLP toxicity studies of **89** with a 4-week repeated dose in rats and monkeys were conducted to examine a wide safety margin. Furthermore, **89** was designated an orphan drug for IPF by the FDA in August 2019 [56], and a phase I clinical trial (a randomized, parallel-assignment, double-blind, placebo-controlled; ACTRN12619001239156) began in Australia in September 2019. The goal of the study is to assess the safety, tolerability, and pharmacokinetic properties of single- and multiple-ascending doses of **89** compared with placebo following oral

administration in healthy volunteers (expected n = 80) [57]. The study was conducted in two parts: part A (single-ascending dose, 6 cohorts, 8 subjects/cohort) and part B (multiple-ascending dose, 4 cohorts, 8 subjects/cohort). In part A, 2 subjects in each cohort received placebo, and 6 subjects received a single dose (100 mg, 200 mg, 500 mg, or 800 mg) of **89**. In part B, 2 subjects in each cohort were given placebo, and 6 subjects received multiple doses (25 mg, 75 mg, 150 mg, or 300 mg) every 12 hours for 14 days. The safety and tolerability of **89** patients were evaluated in each cohort prior to dose escalation. Blood samples for PK and PD analysis were collected at certain time points from the pre-dose of **89** through 72 hours post-dose. The preliminary results showed that human ProRS was significantly overexpressed compared to normal lung tissue from IPF patients [55]. This phase I study is expected to be completed in October 2020, and more detailed clinical results are expected to be reported soon.

4.2. **CRS3123**, prokaryotic methionyl-tRNA synthetase (pMetRS) inhibitor

Crestone, under license from Cardiovascular Systems, developed the antibiotic **CRS3123** (**90**) (Figure 19) (formerly **REP3123**), a prokaryotic methionyl-tRNA synthetase (pMetRS) inhibitor, for the oral treatment of *Clostridium difficile* infection (CDI) and *Helicobacter pylori* infection (HPI) [58]. Notably, **90** prevents protein synthesis by inhibiting *C. difficile* MetRS with high specificity ($K_i = 0.020$ nM) and high selectivity (>1000-fold over human MetRS). The *in vitro* efficacy of **90** was estimated against numerous clinical isolates of *C. difficile* and epidemic strains BI/NAP1/027 (n=108), showing MIC values of 0.25 ~ 1 mg/L [59]. While **90** did not exhibit activity against most gram-negative) bacteria, it has high potency ($MIC_{90} < 1$ mg/L) against clinically important gram-positive bacteria, including *Staphylococcus aureus*, *Streptococcus pyogenes*, *Enterococcus faecalis* and *Enterococcus faecium*, which are resistant to current antimicrobial agents. In a clindamycin-induced hamster model of CDI, **90** demonstrated superior efficacy to vancomycin, reducing the production of toxins and spores from *C. difficile* [60-61]. Consequently, **90** was suggested as a promising candidate for the

treatment of CDI with special features, including (1) a novel mode of action with maintaining activity against pre-existing resistances; (2) high selectivity and potency against a narrow spectrum of *C. difficile* while not affecting normal intestinal microbiota; and (3) the inhibition of toxin production and spore formation from *C. difficile*, alleviating the severity and spread of the disease [62].

4.2.1. Phase I trial of a single dose of CRS3123 (NCT01551004).

In May 2012, the first-time-in-human (FTIH), randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study (NCT01551004) was initiated in the US to assess the safety and pharmacokinetics of **90** after a single oral dose in healthy adults. Five cohorts of eight subjects received **90** or placebo each in a 3:1 ratio [63]; **90** was supplied in 100 and 200 mg capsules, and cohorts A through E received a single oral dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1,200 mg, respectively. The clinical data reported by Crestone, Inc. in 2017 showed that no serious adverse events or immediate allergic reactions were observed during the study [64]. In the **90**-treated groups, hemoglobin reduction, headache, and abnormal urine analysis were the most frequent adverse events, which were mild to moderate and dose independent. The increase in the absorption rate of **90** was less than dose proportional, and the relative bioavailability of the 1200 mg dose group was lower than that of the 800 mg dose group, partially due to the metabolism of glucuronidation at amino groups of **90**. The phase I study showed the safety and tolerability of **90** within the dose ranges and led to further investigation of **CRS3123** for the treatment of CDI.

4.2.2. Phase I trial to determine the safety and pharmacokinetics of CRS3123 (NCT02106338).

An additional single center, randomized, placebo-controlled, double-blind, multiple-ascending dose phase I study (NCT02106338) was pursued to evaluate the safety and tolerability of escalating doses of **90** by oral administration to healthy adults [65]. In this study, thirty healthy

subjects aged 18 to 45 years were randomized into three cohorts, receiving either oral doses of 200, 400, and 600 mg **90** (eight subjects per cohort) or placebo (two subjects per cohort) every 12 hours for 10 days. The safety and tolerability and the plasma, urine, and fecal concentrations and systemic exposure of **90** were determined after multiple oral doses for 10 days. The total duration of this study was 46 weeks. Recently, Crestone, Inc. reported the results of this clinical study, showing that **90** was generally safe and well tolerated without serious adverse events (SAEs), severe treatment-emergent adverse events (TEAEs), and any clinically significant cardiac symptoms [62]. Pharmacokinetically, **90** was absorbed rapidly ($T_{\max} = 1 \sim 2$ h), and the half-life in plasma was approximately 5 to 6 hours without accumulation after multiple dosing. The increase in plasma concentrations was less than proportional to the increase in dose. Importantly, the high oral dose of **90** was not fully absorbed, and fecal concentrations of all dosages were considerably above the target MIC₉₀ value of 1 mg/L for pharmacodynamic success. Moreover, **90** was inactive against important commensal anaerobes, such as *Bacteroides*, *Bifidobacteria*, and *Clostridia*, showing favorable microbiome data over other current medications for CDI. The results of the two phase I clinical studies described above assured further clinical evaluation of **90** patients with CDI. According to the Cortellis report (Clarivate Analytics, 2020), a phase II clinical study to evaluate **90** in CDI is being planned, and preclinical evaluation for gastric *Helicobacter pylori* infection (HPI) with or without a proton pump inhibitor is underway [58].

4.3. **GSK3036656**, prokaryotic leucyl-tRNA synthetase (pLeuRS) inhibitor

Prokaryotic leucyl-tRNA synthetase (pLeuRS) plays a crucial role in bacterial protein synthesis and has become one of the major targets for the development of antimicrobial therapeutics. In particular, boron-containing compounds have been investigated as LeuRS inhibitors by GlaxoSmithKline. GSK has been developing **GSK3036656** (**8**) (Figure 4) (other names, **GSK656**; **GSK070**) as a pLeuRS inhibitor for the treatment of *Mycobacterium tuberculosis*

infection (MTBI), in-licensed from Anacor Pharmaceuticals. Notably, **8** inhibits *Mtb* LeuRS ($IC_{50} = 0.20 \mu M$), showing *in vitro* antitubercular activity (*Mtb* H37Rv MIC = $0.02 \mu M$) with high selectivity over human mitochondrial and cytoplasmic LeuRS (IC_{50} of $>300 \mu M$ and $132 \mu M$, respectively) [21]. Moreover, **8** exhibited remarkable PK profiles in mice ($AUC^{PO} 2.94 h \mu g/mL$ with $\sim 100\%$ BA, $Cl = 8.5 mL/min/kg$, $t_{1/2} = 3.6 h$) and *in vivo* efficacy ($ED_{99} = 0.4 mg/kg$) for MTB treatment in acute and chronic TB infection mouse models with superior tolerability (well-tolerated at $300 mg/kg$). The preclinical data of **8** showed that it had a tolerable therapeutic window based on a number of preclinical safety and risk assessment studies, as disclosed at the 26th ECCMID in Amsterdam, the Netherlands in April 2016 [66]. The human efficacious dose was predicted in the range of 0.5 to $2.7 mg/kg/day$, which is lower than that of other antitubercular agents.

4.3.1. First-time-in-human (FTIH) safety and pharmacokinetics (PK) study of GSK3036656 in healthy subjects (NCT03075410).

In March 2017, a randomized, single-group interventional, double-blind, placebo-controlled, phase I, first time-in-human (FTIH) study (NCT03075410) to evaluate the safety, tolerability, and pharmacokinetics of single and repeated doses of **8** in healthy participants (expected $n = 58$) was launched in the UK [67]. The study was conducted in two parts, including part A (single dose, two cohorts, nine subjects/cohort) and part B (repeat dose, four cohorts, ten subjects/cohort). In part A, single doses ($5 mg$, $15 mg$, $25 mg$, or placebo) of **8** were administered orally. In part B, repeat doses ($5 mg$, $15 mg$, or placebo) of **8** were administered orally once a day for 14 days. The increase in the absorption rate was proportional to the increase in both the single dose and 14-day repeat doses [22]. Based on the PK parameters C_{max} and AUC, accumulation with repeated administration increased approximately 2- to 3-fold, and food intake did not influence the PK parameters. Notably, **8** was not easily metabolized in

plasma, but approximately 90% of **8** and 10% of deboronated metabolites by oxidation were detected in urine. Based on drug-related materials detected in urine, the absorbed amounts of **8** from single (25 mg) and repeat (15 mg) dosing were at least 50% and 78%, respectively. From this phase I clinical study completed in August 2017, the safety and tolerability of **8** was acquired after single and multiple doses with no reports of serious adverse events. Importantly, the results from the clinical laboratory, vital signs, ECG, and telemetry presented no cardiotoxicity concerns. Clinical trial simulations (CTS) were performed to predict the dose range of **8** that produces the highest possible early bactericidal activity (EBA₀₋₁₄) for the phase II clinical trial, and 10 to 15 mg was suggested to be the optimal dosage of **8** for TB treatment..

4.3.2. An early bactericidal activity, safety, and tolerability study of GSK3036656 in subjects with drug-sensitive pulmonary tuberculosis (NCT03557281).

In March 2019, an open-label, randomized, sequentially assigned, dose-escalation, phase IIa study (NCT03557281) was initiated to evaluate the bactericidal activity, safety and tolerability of **8** compared to RIFAFOUR[®] e-275 (Sanofi-Aventis) in patients (expected n = 80) with drug-sensitive pulmonary tuberculosis in South Africa [68]. This study is designed to investigate the early bactericidal activity (EBA), safety and tolerability of **8** in four cohorts of subjects with rifampicin-susceptible tuberculosis. The primary objective of this dose-escalation study is to estimate the antituberculosis effect of **8** by counting serial colony forming units (CFU) of MTB in sputum over 14 days. Subjects in each cohort will be treated with either an **8** or standard-of-care (RIFAFOUR[®] e-275) regimen in a 3:1 ratio. The duration of this study for an individual subject is planned to be 5 weeks: 1 week of screening, 2 weeks of treatment, and another 2 weeks of follow-up visit. The reporting of proof-of-concept data is delayed to the first half of 2021 due to the current COVID-19 outbreak [66].

5. Conclusion

Nie *et al.* summarized the roles of ARSs in various immune diseases such as autoimmune diseases, infectious diseases, and tumor immunity and described their role as important regulators and signaling molecules in the development of immune cells [69]. Antisynthetase syndrome (ASSD) is a heterogeneous group of autoimmune diseases including interstitial lung disease (ILD), myositis, mechanic's hands, Raynaud's phenomenon, and arthritis. ASSD is often caused by specific anti-ARS autoantibodies [70], and the specificity of anti-ARS autoantibodies is related to the clinical features, disease severity, and survival of ASSD patients [71-72]. ARSs are also dysregulated in other autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, immune thrombocytopenia, and systemic lupus erythematosus [73-76]. For example, Wang *et al.* analyzed the interaction of IDO-expressing dendrite cells (DCs) and TrpRS-expressing CD4(+) T cells in Graves' disease (GD) patients. In general, indoleamine-2,3-dioxygenase (IDO) and tryptophanyl-tRNA synthetase (TrpRS) are responsible for the metabolism and utilization of tryptophan, respectively, and play important roles in immune regulation [77]. From their analysis, the ratio of serum kynurenine to tryptophan was increased in GD, and increased TrpRS expression from CD4(+) T cells resisted IDO-mediated immunosuppression from DCs [78]. ARSs are also closely related to tumor immunity; that is, tumor cells can regulate the functions of immune cells by secreting ARSs, or tumor-related immune cells can secrete ARSs and affect tumor development. For example, Wellman *et al.* suggested that the direct correlation of ThrRS levels with disease stage in ovarian cancer patients is derived from ThrRS-regulated angiogenesis and immune cell responses [79]. Additionally, Adam *et al.* discovered that cancer cells could upregulate TrpRS in two different ways to adapt to the nutritional stress caused by tryptophan degradation. First, tryptophan depletion caused by the high expression of indoleamine-2,3-dioxygenase-1 (IDO1) and tryptophan-2,3-dioxygenase (TDO2) in LN229 glioblastoma cells upregulates TrpRS expression through the activation of the general control nonderepressible-2 (GCN2) kinase and

phosphorylation of eukaryotic translation initiation factor 2 α (eIF2 α), followed by the activation of activating transcription factor 4 (ATF4). Second, tumor-infiltrating T cells jointly induce the expression of IDO1 and TrpRS in breast cancer, colon carcinoma, and B cell lymphoma by secreting IFN- γ [80]. As far as we understand, no small molecule directly related to the autoimmune diseases caused by ARSs is known. Given the high limitations of current immuno-oncology therapies in the clinic, ARS-regulating small molecules that are related to tumor immunity can also be an interesting area to explore. The important functions of tRNA synthetases in neurological and neuromuscular disorders have been explored recently as well [81]. ARSs have been studied as therapeutic targets predominantly for pathogen-derived infectious diseases because of concerns that ARS catalytic site inhibitors would block translation in normal cells. However, their indispensable role in other human diseases has been explored, and some ARS inhibitors are undergoing clinical studies for fibrosis as an example. Given the vast number of studies reported on the role of ARS in tumors, it is reasonable to expect that more clinical studies will emerge for cancer therapeutics in the near future. The role of ARS in central nervous system disorders has recently been revealed. As such, the relatively unexplored area of ARS as a target for human diseases other than infectious diseases is being explored by burgeoning biological investigations. Upon these advancements in the newly found roles of ARSs in human diseases, approaches using small molecules targeting ARSs may drive innovative next-generation therapeutic agents.

Author Contributions: All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by NRF-2017M3A9G4052951.

Acknowledgments: We give special thanks to all ARS team members throughout medicinal chemistry, DMPK, and structure biology at NDDC, DGMIF for their hard work.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ibba, M.; Soll, D. Aminoacyl-tRNA Synthesis. *Annu. Rev. Biochem.* **2000**, *69*, 617-650.
2. Yao, P.; Fox, P.L. Aminoacyl-tRNA synthetases in medicine and disease. *EMBO Mol. Med.* **2013**, *5*, 332–343.
3. Fang, P.; Guo, M. Evolutionary limitation and opportunities for developing tRNA synthetase inhibitors with 5-binding-mode classification. *Life (Basel)* **2015**, *5*, 1703–1725.
4. Hurdle, J.G.; O'Neill, A.J.; Chopra, I. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. *Antimicrob. Agents Chemother.* **2005**, *49*, 4821–4833.
5. Agarwalab, V.; Nair, S.K. Aminoacyl tRNA synthetases as targets for antibiotic development. *Med. Chem. Commun.* **2012**, *3*, 887-898.
6. Lv, P.-C.; Zhu, H.-L. Aminoacyl-tRNA synthetase inhibitors as potent antibacterials. *Curr. Med. Chem.* **2012**, *19*, 3550-3563.
7. Gadakh, B.; Aerschot, A.V. Aminoacyl-tRNA synthetase inhibitors as antimicrobial agents: a patent review from 2006 till present. *Expert Opin. Ther. Pat.* **2012**, *22*, 1453-1465.
8. Vondenhoff, G. H.M.; Aerschot, A.V. Aminoacyl-tRNA synthetase inhibitors as potential antibiotics. *Eur. J. Med. Chem.* **2011**, *46*, 5227-5236.
9. Lee, E.-Y.; Kim, S.; Kim, M.H. Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseases. *Biochem. Pharmacol. (Amsterdam, Neth.)* **2018**, *154*, 424-434.
10. Keller, T.L.; Zocco, D.; Sundrud, M.S.; Hendrick, M.; Edenius, M.; Yum, J.; Kim, Y.-J.; Lee, H.-K.; Cortese, J.F.; Wirth, D.F.; Dignam, J.D.; Rao, A.; Yeo1, C.-Y.; Mazitschek, R.; Whitma, M. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. *Nat. Chem. Biol.* **2012**, *8*, 311-317.

11. Shibata, A.; Kuno, M.; Adachi, R.; Sato, Y.; Hattori, H.; Matsuda, A.; Okuzono, Y.; Igaki, K.; Tominari, Y.; Takagi, T.; Yabuki, M.; Okaniwa, M. Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy. *PLoS One* **2017**, *12*, e0186587.
12. Kawamura, T.; Liu, D.; Towle, M.J.; Kageyama, R.; Tsukahara, N.; Wakabayashi, T.; Littlefield, B.A. Anti-angiogenesis effects of borrelidin are mediated through distinct pathways: Threonyl-tRNA synthetase and caspases are independently involved in suppression of proliferation and induction of apoptosis in endothelial cells. *J. Antibiot.* **2003**, *56*, 709-71.
13. Otani, A.; Otani, A.; Slike, B.M.; Dorrell, M.I.; Hood, J.; Kinder, K.; Ewalt, K.L.; Cheresch, D.; Schimmel, P.; Friedlander, M. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 178–183.
14. Kwon, N.H.; Fox, P.L.; Kim, S. Aminoacyl-tRNA synthetases as therapeutic targets. *Nat. Rev. Drug Discovery* **2019**, *18*, 629–650.
15. Si, Y.; Basak, S.; Li, Y.; Merino, J.; Iuliano, J.N.; Walker, S.G.; Peter, J.T. Antibacterial Activity and Mode of Action of a Sulfonamide-Based Class of Oxaborole Leucyl-tRNA-Synthetase Inhibitors. *ACS Infect. Dis.* **2019**, *5*, 1231–1238.
16. Francklyn, C.S.; Mullen, P. Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics. *J. Biol. Chem.* **2019**, *294*, 5365–5385.
17. Rock, F.L.; Mao, W.; Yaremchuk, A.; Tukalo, M.; Crepin, T.; Zhou, H.; Zhang, Y.K.; Hernandez, V.; Akama, T.; Baker, S.J.; Plattner, J.J.; Shapiro, L.; Martinis, S.A.; Benkovic, S.J.; Cusack, S.; Alley, M.R. An antifungal agent inhibits an aminoacyl tRNA synthetase by trapping tRNA in the editing site. *Science* **2007**, *316*, 1759–1761.

18. Dowlut, M.; Hall, D.G. An improved class of sugarbinding boronic acids, soluble and capable of complexing glycosides in neutral water. *J. Am. Chem. Soc.* **2006**, *128*, 4226–4227.
19. Berube, M.; Dowlut, M.; Hall, D.G. Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: Structure and selectivity of complex formation. *J. Org. Chem.* **2008**, *73*, 6471–6479.
20. Palencia, A.; Li, X.; Bu, W.; Choi, W.; Ding, C.Z.; Easom, E.E.; Feng, L.; Hernandez, V.; Houston, P.; Liu, L.; Meewan, M.; Mohan, M.; Rock, F.L.; Sexton, H.; Zhang, S.; Zhou, Y.; Wan, B.; Wang, Y.; Franzblau, S.G.; Woolhiser, L.; Gruppo, V.; Lenaerts, A.J.; O'Malley, T.; Parish, T.; Cooper, C.B.; Waters, M.G.; Ma, Z.; Ioerger, T.R.; Sacchettini, J.C.; Rullas, J.; Angulo-Barturen, I.; Pérez-Herrán, E.; Mendoza, A.; Barros, D.; Cusack, S.; Plattner, J.J.; Alley, M.R.K. Discovery of novel oral protein synthesis inhibitors of *Mycobacterium tuberculosis* that target leucyl-tRNA synthetase. *Antimicrob. Agents Chemother.* **2016**, *60*, 6271–6280.
21. Xianfeng, L.; Vincent, H.; Fernando, L.R.; Wai, C.; Yvonne S.L.; Mak, M.M.; Weimin, M.; Yasheen Z.; Eric, E.E.; Jacob, J.; Plattner, W.Z.; Esther, P.-H.; Ilaria, G.; Alfonso, M.-L.; Carlos, A.; Joaquín, R.; Iñigo, A.-B.; Sabrinia, C.; Fátima, O.; David, B.; Alley, M.R.K. Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). *J. Med. Chem.* **2017**, *60*, 8011–8026.
22. David, T.; Geo, D.; Alex, C.; John, T.; Matt, D.; Simon, C.; Stephanie, G.; Alison, G.; Adeep, P.; Morris, M.; Joaquin, R.-T.; Alfonso, M.-L.; Andrew, S.; David, B.-A. First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment. *Antimicrob. Agents Chemother.* **2019**, *63*, e00240-19.

23. Hoepfner, D.; McNamara, C.W.; Lim, C.S.; Studer, C.; Riedl, R.; Aust, T.; McCormack, S.L.; Plouffe, D.M.; Meister, S.; Schuierer, S.; Plikat, U.; Hartmann, N.; Staedtler, F.; Cotesta, S.; Schmitt, E.K.; Petersen, F.; Supek, F.; Glynne, R.J.; Tallarico, J.A.; Porter, J.A.; Fishman, M.C.; Bodenreider, C.; Diagana, T.T.; Movva, N.R.; Winzeler, E.A. Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. *Cell Host Microbe* **2012**, *11*, 654–663.
24. Sun, W.; Huang, X.; Li, H.; Tawa, G.; Fisher, E.; Tanaka, T.Q.; Shinn, P.; Huang, W.; Williamson, K.C.; Zheng, W. Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening. *Malar. J.* **2017**, *16*, 147.
25. Wampfler, R.; Hofmann, N.E.; Karl, S.; Betuela, I.; Kinboro, B.; Lorry, L.; Silkey, M.; Robinson, L.J.; Mueller, I.; Felger, I. Effects of liver-stage clearance by Primaquine on gametocyte carriage of *Plasmodium vivax* and *P. falciparum*. *PLoS Neglected Trop. Dis.* **2017**, *11*, e0005753.
26. Rusch, M.; Thevenon, A.; Hoepfner, D.; Aust, T.; Studer, C.; Patoor, M.; Rollin, P.; Livendahl, M.; Ranieri, B.; Schmitt, E.; Spanka, C.; Gademann, K.; Bouchez, L.C. Design and synthesis of metabolically stable tRNA synthetase inhibitors derived from cladosporin. *ChemBioChem* **2019**, *20*, 644-649.
27. Fang, P.; Han, H.; Wang, J.; Chen, K.; Chen, X.; Guo, M. Structural Basis for Specific Inhibition of tRNA Synthetase by an ATP Competitive Inhibitor. *Chem. Biol.* **2015**, *22*, 734-744.

28. Zhou, J.; Zheng, L.; Hei, Z.; Li, W.; Wang, J.; Yu, B.; Fang, P. Atomic Resolution Analyses of Isocoumarin Derivatives for Inhibition of Lysyl-tRNA Synthetase. *ACS Chem. Biol.* **2020**, *15*, 1016–1025.
29. Baragaña, B.; Forte, B.; Choi, R.; Hewitt, S.N.; Bueren-Calabuig, J.A.; Pisco, J.P.; Peet, C.; Dranow, D.M.; Robinson, D.A.; Jansen, C.; Norcross, N.R.; Vinayak, S.; Anderson, M.; Brooks, C.F.; Cooper, C.A.; Damerow, S.; Delves, M.; Dowers, K.; Duffy, J.; Edwards, T.E.; Hallyburton, I.; Horst, B.G.; Hulverson, M.A.; Ferguson, L.; Jiménez-Díaz, M.B.; Jumani, R.S.; Lorimer, D.D.; Love, M.S.; Maher, S.; Matthews, H.; McNamara, C.W.; Miller, P.; O'Neill, S.; Ojo, K.K.; Osuna-Cabello, M.; Pinto, E.; Post, J.; Riley, J.; Rottmann, M.; Sanz, L.M.; Scullion, P.; Sharma, A.; Shepherd, S.M.; Shishikura, Y.; Simeons, F.R.C.; Stebbins, E.E.; Stojanovski, L.; Straschil, U.; Tamaki, F.K.; Tamjar, J.; Torrie, L.S.; Vantaux, A.; Witkowski, B.; Wittlin, S.; Yogavel, M.; Zuccotto, F.; Angulo-Barturen, I.; Sinden, R.; Baum, J.; Gamo, F.-J.; Mäser, P.; Kyle, D.E.; Winzeler, E.A.; Myler, P.J.; Wyatt, P.G.; Floyd, D.; Matthews, D.; Sharma, A.; Striepen, B.; Huston, C.D.; Gray, D.W.; Fairlamb, A.H.; Pislakov, A.V.; Walpole, C.; Read, K.D.; Van Voorhis, W.C.; Gilbert, I.H. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. *Proc. Natl. Acad. Sci. U. S. A.* **2019**, *116*, 7015–7020.
30. Novoa, E.M.; Camacho, N.; Tor, A.; Wilkinson, B.; Moss, S.; Marín-García, P.; Azcárate, I.G.; Bautista, J.M.; Mirando, A.C.; Francklyn, C.S.; Varon, S.; Royo, M.; Cortés, A.; de Pouplana, L.R. Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, E5508–E5517.
31. Kim, D.G.; Lee, J.Y.; Kwon, N.H.; Fang, P.; Zhang, Q.; Wang, J.; Young, N.L.; Guo, M.; Cho, H.Y.; Mushtaq, A.U.; Jeon, Y.H.; Choi, J.W.; Han, J.M.; Kang, H.W.; Joo, J.E.; Hur, Y.; Kang, W.; Yang, H.; Nam, D.-H.; Lee, M.-S.; Lee, J.W.; Kim, E.-S.; Moon, A.; Kim, K.;

- Kim, D.; Kang, E.J.; Moon, Y.; Rhee, K.H.; Han, B.W.; Yang, J.S.; Han, G.; Yang, W.S.; Lee, C.; Wang, M.-W.; Kim, S. Chemical inhibition of prometastatic lysyl-tRNA synthetase–laminin receptor interaction. *Nat. Chem. Biol.* **2014**, *10*, 29-34.
32. Kim, D.G.; Choi, J.W.; Lee, J.Y.; Kim, H.; Oh, Y.S.; Lee, J.W.; Tak, Y.K.; Song, J.M.; Razin, E.; Yun, S.-H.; Kim, S. Interaction of two translational components, lysyl-tRNA synthetase and p40/37LRP, in plasma membrane promotes laminin-dependent cell migration. *FASEB J.* **2012**, *26*, 4142–4159.
33. Herman, J.D.; Rice, D.P.; Ribacke, U.; Silterra, J.; Deik, A.A.; Moss, E.L.; Broadbent, K.M.; Neafsey, D.E.; Desai, M.M.; Clish, C.B.; Mazitschek, R.; Wirth, D.F. A genomic and evolutionary approach reveals non-genetic drug resistance in malaria. *Genome Biol.* **2014**, *15*, 511.
34. Kershenovich, D.; Fierro, F.J.; Rojkind, M. The relationship between the free pool of proline and collagen content in human liver cirrhosis. *J. Clin. Invest.* **1970**, *49*, 2246-2249.
35. Mendes, M.I.; Gutierrez Salazar, M.; Guerrero, K.; Thiffault, I.; Salomons, G.S.; Gauquelin, L.; Tran, L.T.; Forget, D.; Gauthier, M.S.; Waisfisz, Q.; Smith, D.E.C.; Simons, C.; van der Knaap, M.S.; Marquardt, I.; Lemes, A.; Mierzevska, H.; Weschke, B.; Koehler, W.; Coulombe, B.; Wolf, N. I.; Bernard, G. Bi-allelic mutations in EPRS, encoding the glutamyl-prolyl-aminoacyl-tRNA synthetase, cause a hypomyelinating leukodystrophy. *Am. J. Hum. Genet.* **2018**, *102*, 676-684.
36. **Clinical trials related to halogifunone.** US National Library of Medicine. <https://clinicaltrials.gov/ct2/results?cond=&term=halofuginone&cntry=&state=&city=&di st=> (accessed on 19 Oct. 2020).

37. NCT01847573, Safety, Tolerability, and pharmacokinetics of single and multiple doses of HT-100 in Duchenne Muscular Dystrophy.
38. NCT02525302, HT-100 Long-term study in DMD patients who completed HALO-DMD-02.
39. NCT01978366, Open label extension study of HT-100 in patients with DMD.
40. Wu, J.; Subbaiah, K.C.V.; Xie, L.H.; Jiang, F.; Khor, E.-S.; Mickelsen, D.; Myers, J.R.; Tang, W.H.W.; Yao, P. Glutamyl-prolyl-tRNA synthetase regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. *Circ. Res.* **2020**, *127*, 827-846.
41. Kim, D.G.; Lee, J.Y.; Lee, J.-H.; Cho, H.Y.; Kang, B.S.; Jang, S.-Y.; Kim, M.H.; Guo, M.; Han, J.M.; Kim, S.-J.; Kim, S. Oncogenic mutation of AIMP2/p38 inhibits its tumorsuppressive interaction with Smurf2. *Cancer Res.* **2016**, *76*, 3422–3436.
42. Yum, M.K.; Kang, J.-S.; Lee, A.-E.; Jo, Y.-W.; Seo, J.-Y.; Kim, H.-A.; Kim, Y.-Y.; Seong, J.; Lee, E.B.; Kim, J.-H.; Han, J.M.; Kim, S.; Kong, Y.-Y. AIMP2 controls intestinal stem cell compartments and tumorigenesis by modulating Wnt/ β -catenin signaling. *Cancer Res.* **2016**, *76*, 4559–4568.
43. Choi, J.W.; Lee, J.-W.; Kim, J.K.; Jeon, H.-K.; Choi, J.-J.; Kim, D.G.; Kim, B.-G.; Nam, D.-H.; Kim, H.J.; Yun, S.H.; Kim, S. Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. *J. Mol. Cell Biol.* **2012**, *4*, 164–173.
44. Lim, S.; Cho, H.Y.; Kim, D.G.; Roh, Y.; Son, S.-Y.; Mushtaq, A.U.; Kim, M.; Bhattarai, D.; Sivaraman, A.; Lee, Y.; Lee, J.; Yang, W.S.; Kim, H.K.; Kim, M.H.; Lee, K.; Jeon, Y.H.; Kim, S. Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development. *Nat. Chem. Biol.* **2020**, *16*, 31–41.

45. Sivaraman, A.; Kim, D.G.; Bhattarai, D.; Kim, M.; Lee, H.Y.; Lim, S.; Kong, J.; Goo, J.-I.; Shim, S.; Lee, S.; Suh, Y.-G.; Choi, Y.; Kim, S.; Lee, K. Synthesis and structure–activity relationships of arylsulfonamides as AIMP2-DX2 inhibitors for the development of a novel anticancer therapy. *J. Med. Chem.* **2020**, *63*, 5139-5158.
46. Lee, S.; Kim, D.G.; Kim, K.; Kim, T.; Lim, S.; Kong, H.; Kim, S.; Suh, Y.-G. 2-Aminophenylpyrimidines as novel inhibitors of aminoacyl-tRNA synthetase interacting multifunctional protein 2 (AIMP2)-DX2 for lung cancer treatment. *J. Med. Chem.* **2020**, *63*, 3908–3914.
47. Yang, X.-L.; Mo, Z.; Schimmel, P. Inhibition of neddylation using glycyl-tRNA synthetase (GlyRS) inhibitors for cancer therapy. WO 2017066459 A1, April 20, 2017.
48. Finn, P.W.; Charlton, M.; Edmund, G.; Jirgensons, A.; Loza, E. 2-Amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase and their preparation. WO 2018065611 A1, April 12, 2018.
49. Jirgensons, A.; Loza, E.; Charlton, M.; Finn, P.W.; Ribas de Pouplana, L.; Saint-Leger, A. Preparation of novel N-acyl-arylsulfonamide derivatives as aaRS inhibitors. WO 2016129983 A1, August 18, 2016.
50. Buckner, F.S.; Alvarez, X.B.; Fan, E.; Gillespie, J.R.; Hol, W.G.J.; Huang, W.; Koh, C.Y.; Ranade, R.M.; Shibata, S.; Verlinde, C.L.M.; Zhang, Z. Preparation of substituted imidazopyridines and analogs as specific inhibitors of methionyl-tRNA synthetase. WO 2016029146 A1, February 25, 2016.
51. Martin, S.F.; Sahn, J.J.; Meis, A.R.; Lepovitz, L.T. Novel inhibitors of trypanosoma brucei methionyl t-RNA synthetase for the treatment of african trypanosomiasis. WO 2016004297 A1, January 7, 2016.

52. Kahne, D.E.; Baidin, V. Preparation of secondary amine compounds as tRNA synthetase inhibitors useful in killing Gram-negative Bacteria. WO 2019140265 A1, July 18, 2019.
53. Lee, B.-Y.; Cho, M.-J.; Lee, H.-G.; Jung, M.-G.; Oh, Y. Heterocyclic compounds, preparation methods, pharmaceutical compositions, and use as prolyl-tRNA synthetase inhibitors. WO 2018147626 A1, August 16, 2018.
54. Qi, X.; Khaybullin, R.; Liang, X. Preparation of sulfamide adenosine derivatives as antitumor, antiinflammatory, antibacterial, antifungal, and parasiticide agents. WO 2016201374 A1, December 15, 2016.
55. Lee, C.H.; Cho, M.; Kim, J.M.; Lee, J.H.; Kim, D.-W.; Park, M.Y.; Kim, Y.K.; Han, J.; Park, J.S. A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis. *Am. J. Respir. Crit. Care Med.* **2020**, *201*, A2786.
56. 2020 Clarivate analytics, The Cortellis™ report of DWN12088, 1-14 (created on 08 Oct 2020).
57. Australian New Zealand Clinical Trials Registry. <http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377846> (accessed on 03 Oct 2020).
58. 2020 Clarivate analytics, The Cortellis™ report of CRS3123, 1-12 (created on 08 Oct 2020).
59. Critchley, I.A.; Green, L.S.; Young, C.L.; Bullard, J.M.; Evans, R.J.; Price, M.; Jarvis, T.C.; Guiles, J.W.; Janjic, N.; Ochsner, U.A. Spectrum of activity and mode of action of REP3123, a new antibiotic to treat *Clostridium difficile* infections. *J. Antimicrob. Chemother.* **2009**, *63*, 954–963.

60. Ochsner, U.A.; Bell, S.J.; O'Leary, A.L.; Hoang, T.; Stone, K.C.; Young, C.L.; Critchley, I.A.; Janjic, N. Inhibitory effect of REP3123 on toxin and spore formation in *Clostridium difficile*, and *in vivo* efficacy in a hamster gastrointestinal infection model. *J. Antimicrob. Chemother.* **2009**, *63*, 964-971.
61. Citron, D.M.; Warren, Y.A.; Tyrrell, K.L.; Merriam, V.; Goldstein, E.J.C. Comparative *in vitro* activity of REP3123 against *Clostridium difficile* and other anaerobic intestinal bacteria. *J. Antimicrob. Chemother.* **2009**, *63*, 972-976.
62. Lomeli, B.K.; Galbraith, H.; Schettler, J.; Saviolakis, G.A.; El-Amin, W.; Osborn, B.; Ravel, J.; Hazleton, K.; Lozupone, C.A.; Evans, R.J.; Bell, S.J.; Ochsner, U.A.; Jarvis, T.C.; Baqar, S.; Janjic, N. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. *Antimicrob. Agents Chemother.* **2020**, *64*, e01395-19.
63. US National Library of Medicine. <https://clinicaltrials.gov/ct2/show/NCT01551004> (accessed on 04 Oct 2020).
64. Nayak, S.U.; Griffiss, J.M.; Blumer, J.; O'Riordan, M.A.; Gray, W.; McKenzie, R.; Jurao, R.A.; An, A.T.; Le, M.; Bell, S.J.; Ochsner, U.A.; Jarvis, T.C.; Janjic, N.; Zenilman, J.M. Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of *Clostridium difficile*, in a Phase 1 Study. *Antimicrob. Agents Chemother.* **2017**, *61*, e02760-16.
65. US National Library of Medicine. <https://clinicaltrials.gov/ct2/show/NCT02106338> (accessed on 05 Oct 2020).

66. 2020 Clarivate analytics, The Cortellis™ report of GSK3036656, 1-13 (created on 08 Oct 2020).
67. US National Library of Medicine. <https://clinicaltrials.gov/ct2/show/NCT03075410> (accessed on 08 Oct 2020).
68. US National Library of Medicine. <https://clinicaltrials.gov/ct2/show/record/NCT03557281> (accessed on 09 Oct 2020).
69. Nie, A.; Sun, B.; Fu, Z.; Yu, D. Roles of aminoacyl-tRNA synthetases in immune regulation and immune diseases. *Cell Death Dis.* **2019**, *10*, 901.
70. Mahler, M.; Miller, F.W.; Fritzler, M.J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. *Autoimmun. Rev.* **2014**, *13*, 367–371.
71. Lega, J.C.; Fabien, N.; Reynaud, Q.; Durieu, I.; Durupt, S.; Dutertre, M.; Cordier, J.-F.; Cottin, V. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. *Autoimmun. Rev.* **2014**, *13*, 883–891.
72. Pinal-Fernandez, I.; Casal-Dominguez, M.; Huapaya, J.A.; Albayda, J.; Paik, J.J.; Johnson, C.; Silhan, L.; Christopher-Stine, L.; Mammen, A.L.; Danoff, S.K. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. *Rheumatology (Oxford)* **2017**, *56*, 999–1007.
73. Koch, M.W.; Illynskyy, Y.; Golubov, A.; Metz, L.M.; Yong, V.W.; Kovalchuk, O. Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis. *Eur. J. Neurol.* **2018**, *25*, 651–658.

74. Chen, J.; Jun, L.; Shiyong, C.; Li, H.; Zhu, M.; Shen, B. Increased TTS expression in patients with rheumatoid arthritis. *Clin. Exp. Med.* **2015**, *15*, 25–30.
75. Wang, C.Y.; Shi, Y.; Min, Y.-N.; Zhu, X.-J.; Guo, C.-S.; Peng, J.; Dong, X.-Y.; Qin, P.; Sun, J.-Z.; Hou, M. Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia. *J. Clin. Immunol.* **2011**, *31*, 643–649.
76. Zhang, Q.; Yin, X.; Wang, H.; Wu, X.; Li, Xin.; Li, Y.; Zhang, X.; Fu, C.; Li, H.; Qiu, Y. Fecal metabolomics and potential biomarkers for systemic lupus erythematosus. *Front. Immunol.* **2019**, *10*, 976.
77. Boasso, A.; Herbeuval, J.P.; Hardy, A.W.; Winkler, C.; Shearer, G.M. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4⁺ T cells. *Blood* **2005**, *105*, 1574–1581.
78. Wang, S.; Mao, C.; Zhao, Z.; Gu, Q.; Jin, M.; Xiao, Y.; Jiang, X.; Zhao, Y.; Zhang, Y.; Ning, G. Increased TTS abrogates IDO-mediated CD4(+) T cells suppression in patients with Graves' disease. *Endocrine* **2009**, *36*, 119–125.
79. Wellman, T. L.; Eckenstein, M.; Wong, C.; Rincon, M.; Ashikaga, T.; Mount, S.L.; Francklyn, C.S.; Lounsbury, K.M. Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer. *BMC Cancer* **2014**, *14*, 620.
80. Adam, I.; Dewi, D.L. Upregulation of tryptophanyl-tRNA synthetase adapts human cancer cells to nutritional stress caused by tryptophan degradation. *Oncoimmunology* **2018**, *7*, e1486353.
81. Boczonadi, V.; Jennings, M.J.; Horvath, R. The role of tRNA synthetases in neurological and neuromuscular disorders. *FEBS Lett.* **2018**, *592*, 703–717.